Galt Pharmaceuticals’ Orphengesic Forte has received a priority review goal date for FDA approval by August 14, 2019. The approval will provide physicians and patients with a non-controlled opioid-free alternative for pain management.
Estimates indicate that 47,600 people died from opioid overdoses in 2017 in the U.S. In addition, from July 2016 to September 2017, there was a 30% increase in the use of opioids.
Orphengesic Forte is an oral, non-controlled, combination muscle-relaxant pain reliever. The tablets contain 50 mg orphenadrine citrate, 770 mg aspirin, and 60 mg caffeine. The drug is indicated for the relief of mild to moderate pain in acute musculoskeletal disorders, in combination with rest and physical therapy.
Source: Business Wire, May 30, 2019